U.S. Transportation Stock News

Arcutis Biotherapeutics (ARQT) is in focus after reporting Q1 2026 revenue of US$105.4 million, a narrowed net loss of US$11.3 million, positive operating cash flow, and reaffirmed full year revenue guidance. See our latest analysis for Arcutis Biotherapeutics. The stock closed at US$20.66 after the results, with a 1-day share price return of -14.52% and a year to date share price return of -28.76%. However, the 1-year total shareholder return is 52.87%, which suggests recent momentum has...

Vaxcyte (PCVX) is back in focus after the company reported a first quarter net loss of US$320.62 million, along with updates on its advancing VAX-31 vaccine trials and an upcoming study for VAX-A1. See our latest analysis for Vaxcyte. The stock has given up some ground recently, with a 1 day share price return of 9.84% decline and a 30 day share price return of 15.18% decline. However, the year to date share price return is 10.8% and the 1 year total shareholder return is 63.69%, suggesting...

Ultragenyx Pharmaceutical: Recent Move in Context Ultragenyx Pharmaceutical (RARE) has drawn fresh attention after its recent trading, with the stock closing at US$26.13. Investors are weighing this price against the company’s mixed return profile across the past year and the past 3 months. See our latest analysis for Ultragenyx Pharmaceutical. The recent move to US$26.13 comes after a 12.87% 1 month share price return and a 10.72% year to date share price return, set against a 27.38% 1 year...

How BridgeBio Pharma stock has been trading BridgeBio Pharma (BBIO) has drawn investor attention after a strong 1 year total return of 93.54%. This contrasts with weaker recent trading, with the stock down 6.2% over the past month and 13.79% year to date. See our latest analysis for BridgeBio Pharma. The recent 1 day and 1 month share price declines sit against a much stronger backdrop, with a 1 year total shareholder return of 93.54% and a 3 year total shareholder return above 3x. This...

CVS Health (CVS) delivered first quarter 2026 earnings that came in ahead of expectations across all segments. This prompted higher full year earnings guidance and fresh attention on its pharmacy, insurance and technology plans. See our latest analysis for CVS Health. The 1-month share price return of 11.68% and 90-day share price return of 11.50% suggest momentum has picked up around the recent earnings beat and raised guidance. The 1-year total shareholder return of 33.46% points to a...

In April 2026, Mirion Technologies reported first-quarter revenue of US$257.6 million, up from US$202.0 million a year earlier, but swung from a small net income to a net loss of US$3.4 million, while also reaffirming its full-year 2026 earnings guidance. A key detail for investors is that Mirion’s full-year revenue growth outlook of approximately 22%–24% includes anticipated benefits from foreign exchange movements and recent acquisitions, which helps explain management’s confidence...

In the past week, OUTFRONT Media Inc. reported first-quarter 2026 results showing sales of US$429.6 million versus US$390.7 million a year earlier and a swing to net income of US$19.1 million, while also declaring a quarterly dividend of US$0.30 per share payable on June 30, 2026. This combination of revenue growth, a return to profitability, and a maintained cash dividend highlights improving operating performance and management’s confidence in the company’s cash generation. We’ll now...

Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused licensing deals and pipeline additions. See our latest analysis for Madrigal Pharmaceuticals. The share price has been volatile, with a 30 day share price return of 4.49% and a 90 day share price return of 11.99%. Yet year to date it is down 9.94%, while the 1 year total shareholder return of...

Sana Biotechnology, Inc. recently drew attention with heavy pre-earnings options activity and elevated implied volatility, ahead of its first-quarter earnings release and its past May 12, 2026 presentation at the BofA Securities Healthcare Conference. Investors are closely watching how Sana’s engineered cell therapy pipeline, including its collaborations with Beam Therapeutics and Mayo Clinic, might feature in these updates. We’ll now examine how this heightened options activity ahead of...

Apollo Global Management (APO) has drawn attention after reporting record fee related earnings and crossing US$1 trillion in assets under management in the first quarter of 2026, alongside higher dividends and reaffirmed guidance. See our latest analysis for Apollo Global Management. The latest results and US$1 trillion AUM milestone come after a mixed price pattern, with a 21.29% 1 month share price return but a 12.84% decline year to date and a 2.58% 1 year total shareholder return. Recent...

In April 2026, Williams-Sonoma, Inc. launched its tenth brand, Dormify, a digital-first concept offering stylish, functional furnishings tailored to dorms and compact living spaces, supported by tools like customizable wish lists, design guidance, and curated checklists. The Dormify rollout also introduced a Pick-Up Near Campus™ program that uses Williams-Sonoma’s 450-plus store network and dedicated concierges to streamline delivery for students and small-space renters. Next, we’ll examine...

In the past quarter, EastGroup Properties reported first quarter 2026 earnings that came in well above prior expectations, prompting analysts to raise their forecasts and highlight stronger near-term growth prospects. This earnings surprise has renewed attention on how the company’s logistics-focused portfolio and development pipeline may support its longer-term investment case. With first quarter earnings outperforming expectations, we’ll now examine how this stronger near-term outlook...

In early May 2026, Life Time Group Holdings reported first-quarter results showing year-on-year increases in sales to US$767.57 million, total revenue to US$788.7 million, and net income to US$88.1 million, alongside higher earnings per share. The company also raised its full-year 2026 revenue and net income guidance, while continuing to open large-format clubs and repurchasing shares, underscoring how earnings growth, expansion, and capital allocation are moving together. We’ll now examine...

Wondering whether NCR Voyix at US$8.09 is starting to look cheap, or still carries too much risk for the price you pay? The stock has moved sharply in the short term, with a 17.4% return over 7 days and 29.2% over 30 days, although returns are negative at 18.0% year to date and 20.4% over 1 year. These recent moves sit against a longer track record that includes 42.7% and 71.8% returns over 3 and 5 years respectively. These figures may reflect shifting sentiment and changing expectations for...

ICON stock performance snapshot after recent moves ICON (ICLR) has caught investor attention after a recent share price move, with the stock closing at $125. Short term returns show mixed momentum, including a 0.7% gain over the past day. Over the past week and month, ICON has recorded returns of 5.6% and 16.6% respectively. Performance over the past 3 months and year to date reflects double digit declines, highlighting uneven sentiment around the stock. See our latest analysis for ICON. That...

In early May 2026, Innoviva, Inc. reported first-quarter 2026 results, with revenue of US$97.99 million and net income of US$186.6 million, marking a clear turnaround from the prior year’s loss. Around the same time, Innoviva filed a US$207.99 million shelf registration for up to 9,000,000 common shares tied to its employee stock ownership plan, underscoring management’s focus on employee alignment alongside growth in its recurring royalty and Specialty Therapeutics businesses. We’ll now...

Why Catalyst Pharmaceuticals Stock Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn attention after a period of strong share-price moves, with returns over the past month, past 3 months and year all in positive territory according to recent performance data. For investors tracking US biopharmaceutical stocks focused on rare diseases, this kind of sustained positive return profile can prompt a closer look at how the current share price relates to earnings, profitability and...

Aurinia Pharmaceuticals (AUPH) has drawn fresh attention after reporting first quarter 2026 results. Revenue was US$77.71 million and net income was US$34.36 million, both higher than the prior year period. See our latest analysis for Aurinia Pharmaceuticals. The earnings beat and reiterated 2026 guidance arrived alongside a 4.9% 90 day share price return and an 86.7% 1 year total shareholder return, suggesting strong recent momentum despite short term share price weakness. If Aurinia’s...

Cimpress plc has reported past third-quarter 2026 results showing sales of US$886.21 million versus US$789.47 million a year earlier, with net income of US$13.84 million compared with a net loss of US$8.24 million and basic earnings per share from continuing operations improving from US$0.33 loss to US$0.57. Over the first nine months to March 31, 2026, Cimpress lifted sales to US$2.79 billion and more than doubled net income to US$70.82 million, highlighting materially stronger...

Walker & Dunlop, Inc. has reported past first-quarter 2026 results, with revenue rising to US$301.33 million and net income to US$15.87 million, alongside affirming a quarterly dividend of US$0.68 per share payable on June 4, 2026. Beneath these headline figures, the company highlighted very large growth in transaction volumes and agency lending, supported by complex refinancing deals and higher productivity per banker that helped increase its share of the GSE lending market. We’ll now...

Jacobs Solutions (NYSE:J) has been selected as part of a joint venture to design five new underground stations for Sydney Metro West. The contract covers integrated engineering design services for Australia’s largest transportation project. The win expands Jacobs Solutions’ global transportation infrastructure footprint, with a focus on high-performance, sustainable mass transit. For investors watching the infrastructure and engineering space, this new Sydney Metro West mandate puts Jacobs...

Why Chemours stock is on investors’ radar Chemours (CC) has drawn fresh attention after its first quarter 2026 earnings, where several business segments outperformed expectations, and management highlighted debt reduction, refinancing activity, and reaffirmed full year sales and EBITDA guidance. See our latest analysis for Chemours. That interest has come against a sharp pullback in recent days, with a 1 day share price return of 5.32% decline and a 7 day share price return of 16.85% decline,...

Stepan Company reported past first-quarter 2026 results showing sales of US$604.51 million versus US$593.26 million a year earlier, but it swung from net income of US$19.71 million to a net loss of US$41.41 million, with basic and diluted loss per share from continuing operations of US$1.81 compared with earnings of US$0.86. Despite the move into loss-making territory, Stepan maintained its shareholder payout by affirming a quarterly dividend of US$0.395 per share, payable on June 15, 2026,...

In April 2026, Seacoast Banking Corporation of Florida reported first-quarter 2026 results, with net interest income rising to US$176.47 million from US$118.52 million a year earlier, while net income was broadly flat at US$31.9 million and diluted EPS from continuing operations eased to US$0.29 from US$0.37. Over the same quarter, Seacoast also completed a buyback of 317,628 shares for US$10.23 million, a small but clear signal of ongoing capital return alongside its mixed earnings...